New drug aims to stop nosebleeds in rare blood vessel disorder

This study tests an experimental drug called ATV-1601 in people with moderate to severe HHT, a condition that causes frequent nosebleeds and anemia. The trial has two parts: first, participants receive either the drug or a placebo to check safety and effectiveness; then, all eligible participants can receive the drug in an open-label extension. The main goal is to see if ATV-1601 can safely reduce the number and severity of nosebleeds.